内镜设备主要企业业务分解课件.pptx

1、414.3640.7922.11,307.5931.056.0101.2175.2276.9161.1-40%0%40%80%120%04008001,2001,600201820162017营业收入（百万元）营业收入 YOY20192020Q1-3扣非归母净利润（百万元）扣非归母净利润 YOY受 疫 情 影 响，医 院 内 镜 诊 疗 量 下 降，公司营收和扣非归 母净利润下滑。22.1%33.0%41.8%44.5%28.2%24.5%19.5%17.7%19.0%15.3%13.1%11.5%5.1%6.9%9.2%12.6%3.5%10.0%7.4%6.8%4.7%6.1%5.7%5.

2、8%9.0%4.7%4.3%3.3%0%20%40%60%80%100%2016止血及闭合类 活检类2017扩张类2018EMR/ESD类2019微波消融针ERCP类EUS/EBUS类 肿瘤消融设备 其他14 1 4.3 6 4 0.7 9 2 2.1 1,3 0 7.5 9 3 1.0 5 6.0200300400500600700止血及闭合类 活检类扩张类EMR/ESD 类 ERCP 类 EUS/EBUS类 2016 2017 2018 20191000%20%40%60%80%2016201720182019止血及闭合类EMR/ESD类活检类ERCP类扩张类EUS/EBUS类20 2 0

3、 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 止血及闭合类 活52.363.868.688.913.02.52.36.360%20%40%60%80%100%02040608010020162017微波消融针微波消融针毛利率20182019微波消融设备微波消融设备毛利率35 2.3 6 3.8 6 8.6 8 8.9 1 3.0 2.5 2.3 6.3 617.837.949.170.40%2%4%6%8%02040608020162017研发投入（百万元）20182019研发投入占总营收的比重%327.5533.979.7%83.6%85.7%784.80%30%60%9

4、0%0300600900201620182017核心技术生产产品带来的收入（百万元）核心技术生产产品带来的收入占总营收的比例%41 7.8 3 7.9 4 9.1 7 0.4 0%2%4%6%8%0 2 0 45558.6%55.1%54.9%58.3%40.6%44.6%44.4%41.4%0%20%40%60%80%100%2016201920172018中国大陆 国外 其他地区39%47%39%14%22%29%60%68%75%28%32%34%43%40%32%25%61%53%33%54%44%28%0%20%40%60%80%100%20162016201620182017201

5、8欧洲20172018美洲2017其他区域经 销 直 销 贴 牌65 8.6%5 5.1%5 4.9%5 8.3%4 0.6%4 4.6%6867199891227125471210613019025310227-80%-60%0%20%40%60%020080010001200140020152018201920Q1-320162017营业收入（百万元）营业收入 YOY归母净利润（百万元）归母净利润 YOY269352407229175232617355233255361119(100)0100600-20%200180116197179400-40%30040050020152016-42

6、0172018-3201920Q1-3销售费用管理费用研发费用财务费用76 8 6 7 1 9 9 8 9 1 2 2 7 1 2 5 4 7 1 2 1 0 6 1 3 0 1 9 0 291%89%88%82%71%68%5%7%13%23%24%6%3%6%4%5%5%7%0%20%40%60%80%100%201520H12016超声诊断设备20172018内窥镜配件及其他2019其他业务44%53%59%64%63%66%0%30%60%90%2015201720H12016超声诊断设备2018内窥镜2019配件及其他18%19%18%19%20%8%7%8%8%10%5%0%10%

7、15%20%25%201520192016研发投入比20172018申万医疗器械平均研发投入比89 1%8 9%8 8%8 2%7 1%6 8%5%7%1 3%2 3%2 499101 0111 151.181.290.3122.1182.89.222.97.337.354.7-100%0%100%200%300%500%050100400%150200201520162017营业收入（百万元）营业收入 YOY20182019归母净利润（百万元）归母净利润 YOY125 1.1 8 1.2 9 0.3 1 2 2.1 1 8 2.8 9.2 2 2.9 77.6%8.5%6.5%6.3%8.4

8、%8.5%7.0%9.1%12.5%5.7%73.0%9.2%16.8%64.7%55.6%0%20%80%100%止血闭合类2017EMR/ESD类2018活检类ERCP类诊疗仪器类2019其他业务0%20%60%40%40%60%80%20192017止血闭合类EMR/ESD类2018活检类ERCP类诊疗仪器类020406080100120止血闭合类EMR/ESD类活检类ERCP类诊疗仪器类2017 2018 2019020000040000060000080000010000001200000止血闭合类EMR/ESD类活检类ERCP类诊疗仪器类20172018 2019137.6%8.5%6.5%6.3%8.4%8.5%7.0%9.6.711.914.90%4%8%12%048121620172018研发费用（百万元）2019研发费用占总营收的比例%85.0115.5172.290%91%92%93%94%95%050100150200201720192018公司核心技术产品收入（百万元）公司核心技术产品收入占主营业务收入比例%146.7 1 1.9 1 4.9 0%4%8%1 2%0 4 8 1 2 1 6 2 0 1151 5161 6171 7